Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients-Reference-Cited by-同舟云学术

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

Published:2017-08-17 Issue:1 Volume:24 Page:104-112
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Collins P. W.¹^ORCID,Quon D. V. K.²,Makris M.³^ORCID,Chowdary P.⁴^ORCID,Kempton C. L.⁵,Apte S. J.⁶,Ramanan M. V.⁷,Hay C. R. M.⁸^ORCID,Drobic B.⁹^ORCID,Hua Y.⁹,Babinchak T. J.¹⁰,Gomperts E. D.¹¹

Affiliation:

1. Arthur Bloom Haemophilia Centre; School of Medicine Cardiff University; Cardiff UK

2. Hemophilia Treatment Center; Orthopaedic Hospital; Los Angeles CA USA

3. Department of Haematology; Royal Hallamshire Hospital; Sheffield UK

4. Katharine Dormandy Haemophilia Care and Thrombosis Unit; Royal Free Hospital NHS Trust; London UK

5. Department of Hematology and Medical Oncology; Emory University; Atlanta GA USA

6. Sahyadri Specialty Hospital; Pune India

7. Jehangir Clinical Development Centre; Jehangir Hospital; Pune India

8. Manchester Haemophilia Comprehensive Care Centre; Manchester UK

9. Clinical Research; Emergent BioSolutions Canada Inc.; Winnipeg MB Canada

10. Clinical Development and Medical Affairs; Emergent BioSolutions Inc.; Berwyn IL USA

11. Consultant for Emergent BioSolutions Inc.; Montrose CO USA

Funder

Cangene Corporation

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13324/fullpdf

Reference14 articles.

1. Christmas disease: a condition previously mistaken for haemophilia;Biggs;BMJ,1952

2. Guidelines for the management of hemophilia;Srivastava;Haemophilia,2013

3. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders: a United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology;Keeling;Haemophilia,2008

4. Characterization of IXINITY(R) (Trenonacog Alfa), a recombinant factor IX with primary sequence corresponding to the threonine-148 polymorph;Monroe;Adv Hematol,2016

5. Reduced immunogenic response to residual CHO cell protein in recombinant factor IX (IB1001) drug product in normal healthy rabbits;Cheung;Haemophilia,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States;Journal of Managed Care & Specialty Pharmacy;2024-08

2. A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B;Journal of Blood Medicine;2024-03

3. Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab;Pirogov Russian Journal of Surgery;2024

4. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2023-05

5. Expert opinion paper on the treatment of hemophilia A with emicizumab;Hematology;2023-01-13